preloader logo

Investor Relations

Changing the scale of what’s possible…

Nautilus Biotechnology seeks to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. By integrating breakthrough innovations in computer science, engineering, and biochemistry we have designed a large-scale, single-molecule proteomic analysis technology capable of delivering extreme sensitivity and scale.

By enabling an expansion of both the depth and breadth of proteomic studies, Nautilus’ technology has the potential to revolutionize how biological research is conducted, drugs are identified and developed, and human disease is treated.

Explore novel Nautilus data and its potential impact on Alzheimer’s disease and related dementias in our new bioRxiv preprint and webinar.

Stock Information

Minimum 15 minutes delayed. Source: LSEG

Presentations

Investor Presentation March 2026

Mar 10, 2026

US HUPO 2026 Data Summary

Feb 24, 2026

Nasdaq Amplify Issuer Spotlight: Nautilus Biotechnology

Nov 01, 2025

Preprint - Development of a method for large-scale single-molecule analysis of tau proteoforms

Jun 27, 2025

Advancing next-generation proteomics with single-molecule Iterative Mapping

Jan 14, 2025